A Phase 2 interventional study of Placebo and NBI-1065845 in Major Depressive Disorder, sponsored by Neurocrine Biosciences. Completed at 41 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-15.
Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Depressive Disorder, Major by Neurocrine Biosciences — 6 open to participants now, 6 under way, 5 of them phase 3. Depressive Disorder, Major · Neurocrine Biosciences.
Among the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences, this one is the 6th largest by enrollment, is the only one that started in 2022, is one of 3 in phase 2, and was the 1st registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →6 of the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences are open now, in 12 countries. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18+
Neurocrine Biosciences · Sites in United States, Australia, Bulgaria and 8 more countries
Ages 18+
Neurocrine Biosciences · Sites in United States, Belgium, Canada and 4 more countries
Ages 18+
Neurocrine Biosciences · Sites in United States, Australia, Belgium and 20 more countries
Ages 18+
Neurocrine Biosciences · Sites in United States, Bulgaria, Lithuania and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2022.
This study's enrollment of 183 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 192 across the 10 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
3 of the studies in Depressive Disorder, Major by Neurocrine Biosciences that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06911112Phase 3Neurocrine BiosciencesNBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
| NCT06963021Phase 3Neurocrine BiosciencesNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
| NCT06786624Phase 3Neurocrine BiosciencesStudy to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of NBI-1065845 compared with placebo in participants with MDD on improving symptoms of depression.
Key Inclusion Criteria:
Participants must meet all of these criteria for inclusion in the study:
Key Exclusion Criteria:
Participants will be excluded from the study if they meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo orally once a day.
Drug: Placebo
Participants will receive low-dose NBI-1065845 orally once a day.
Drug: NBI-1065845
Participants will receive high-dose NBI-1065845 orally once a day.
Drug: NBI-1065845
Matching placebo tablets
NBI-1065845 tablets
Also known as: TAK-653
Change from Baseline in Total Montgomery Åsberg Depression Rating Scale (MADRS) Score at Day 28
Time frame: Baseline, Day 28
Change from Baseline in Total MADRS Score at Day 7, Day 14, and Day 56
Time frame: Baseline, Days 7, 14, and 56
Change from Baseline in Clinical Global Impression - Severity (CGI-S) Score at Day 28 and Day 56
Time frame: Baseline, Days 28 and 56
Response, defined as ≥50% decrease in MADRS from baseline, at Day 28 and Day 56
Time frame: Baseline, Days 28 and 56
Remission, defined as MADRS ≤10, at Days 28 and 56
Time frame: Days 28 and 56
Change from Baseline in Patient Health Questionnaire-9 (PHQ-9) Score at Day 28 and Day 56
Time frame: Baseline, Days 28 and 56
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2022 to primary completion in Jan 2024, 22 months.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 22 months is above that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osavampator